Researchers will find all the information they need about each molecule, including any possible uses, in this comprehensive review. This article will talk about potential hypothesized properties such as:
- Blood levels of insulin-like growth factor 1
- Muscle cell proliferation
- Bone density increases
We will also discuss how hGH and Ipamorelin work, potential effects, and mechanisms of action. Finally, trained scientists can find out where to get Ipamorelin for lab and in vitro experimentation.
HGH: What is it?
Somatropin and synthetic growth hormone (hGH) are interchangeable terms for the same 191-amino acid protein. It is manufactured in a controlled environment using recombinant DNA technology to create a replica of the GH sequence. Recombinant hGH (rhGH) describes this hormone when synthesized outside the organism.
In 1981, the American biotechnology company Genentech created recombinant hGH for the context of growth hormone deficiency (GHD). Inadequate GH production in GHD has been linked to metabolic and developmental issues within the organism. It may also potentially enhance blood GH levels efficiently and concentration-dependently. Today, there are many different peptides with growth hormones, and you can easily research which peptides for muscle growth suit your needs.
Ipamorelin Peptide: What is it?
A pentapeptide called Ipamorelin (NNC 26-0161) is synthesized in a lab, and it may bind to the ghrelin receptors. The pituitary gland contains ghrelin receptors called growth hormone secretagogue (GHS) receptors. Growth hormone (GH) production is enhanced when these receptors are activated. Novo Nordisk and Helsinn Therapeutics invented Ipamorelin in 1994 to mimic the action of ghrelin in the intestines and increase peristalsis.
Also, unlike other, less selective GHSs, this peptide has been hypothesized to stimulate GH synthesis in the anterior pituitary exclusively, leaving the production of other hormones like prolactin and ACTH unaffected. This suggested potential for the context of post-surgical ileus, a paralysis of the intestines that occurs in gastrointestinal surgery. Ipamorelin suggested promise in phase-2 studies for the disease, but the outcomes weren’t considered clinically meaningful after 7–10 days of presentation. Therefore, the trials were halted.
Shortly after being presented, Ipamorelin is believed to cause a dramatic increase in GH levels, as suggested by the research. The effects of its GH-boosting presentation seem to last two to three hours since it may have a half-life of less than two hours.
Ipamorelin vs. HGH: A Thorough Comparison
Research models with fully functioning pituitary glands have suggested that hGH and Ipamorelin might consistently elevate hGH levels. Direct measurement of blood GH levels after Ipamorelin presentation or indirect measurement of insulin-like growth factor-1 (IGF-1) levels after hGH supplementation may be used to evaluate this impact. Growth hormone primarily acts as an anabolic mediator via IGF-1. Scientists speculate that the following may be some of the most significant effects of hGH:
- Research models of GHD given recombinant hGH daily at physiological concentrations appear to have their IGF-1 synthesis upregulated. IGF-1 levels were measured after four months of presentation, rising from 98 mcg/l, the lowest limit of the reference range, to 323 mcg/l.
- The research purported that research models with HIV-associated muscle wasting appeared to exhibit a significant gain in lean mass after three months of presentation after receiving supraphysiological levels of hGH.
Investigations purport that Ipamorelin seems effective because it may promote the production of GH. Thus, it has been hypothesized the peptide can only increase GH levels in functioning pituitary glands. Findings imply that Ipamorelin may be better than hGH at promoting weight gain and, at large concentrations, may even induce supraphysiological GH levels.
In preclinical research, it has been speculated that Ipamorelin may enhance hunger and growth hormone levels, leading to increased weight gain in experimental animals. The peptide seemed to have caused a 16.9% rise in body weight in healthy mice, lower than the 27.5% increase speculated with hGH treatment. In contrast, the Ipamorelin group appeared to have the most weight increase in the first two weeks, and the peptide itself did not seem to induce other effects.
hGH Properties
Growth hormone (hGH) research has asserted several positive potential actions, particularly in growth hormone deficiency (GHD), which the compound may aid, hypothesized to alleviate symptoms including fatigue, muscular atrophy, and fat cells.
Click here to be redirected to the Core Peptides website for more educational articles and the highest-quality research compounds available for sale.
References
[i] Brinkman JE, Tariq MA, Leavitt L, et al. Physiology, Growth Hormone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482141/
[ii] Chung, J. Y., Sunwoo, J. S., Kim, M. W., & Kim, M. (2015). The neuroprotective effects of human growth hormone as a potential treatment for amyotrophic lateral sclerosis. Neural regeneration research, 10(8), 1201–1203. https://doi.org/10.4103/1673- 5374.162690
[iii] Flodh H. (1986). Human growth hormone produced with recombinant DNA technology: development and production. Acta paediatrica Scandinavica. Supplement, 325, 1–9. https://doi.org/10.1111/j.1651- 2227.1986.tb10356.x
[iv] Ayyar V. S. (2011). History of growth hormone therapy. Indian journal of endocrinology and metabolism, 15 Suppl 3(Suppl3), S162–S165. https://doi.org/10.4103/2230-8210.84852
[v] Navarro, R., Dunn, J. D., Lee, P. A., Owens, G. M., & Rapaport, R. (2013). Translating clinical guidelines into practice: the effective and appropriate use of human growth hormone. The American journal of managed care, 19(15 Suppl), s281–s289.
[vi] Cai, Y., Xu, M., Yuan, M., Liu, Z., & Yuan, W. (2014). Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. International journal of nanomedicine, 9, 3527–3538. https://doi.org/10.2147/IJN.S63507
[vii] Johansen, N. L., Lau, J., Madsen, K., Lundt, B. F., Hansen, B. S., & Peschke, B. (1998). US Patent No. 5,767,085. Washington, DC: US Patent and Trademark Office.
[viii] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
